Open access
Open access
Powered by Google Translator Translator

Allergy & Immunology

‘Everyone was left to guess what went wrong’: An open letter to AstraZeneca’s CEO on transparency

10 Sep, 2020 | 09:40h | UTC

‘Everyone was left to guess what went wrong’: An open letter to AstraZeneca’s CEO on transparency – STAT

 

Commentary on Twitter

 

AstraZeneca Covid-19 vaccine study put on hold due to suspected adverse reaction in participant in the U.K.

9 Sep, 2020 | 09:45h | UTC

AstraZeneca Covid-19 vaccine study put on hold due to suspected adverse reaction in participant in the U.K. – STAT

 

Commentary on Twitter

 

[Preprint] Randomized trial: Convalescent plasma not associated with improved outcomes in Covid-19

9 Sep, 2020 | 09:41h | UTC

Convalescent plasma in the management of moderate COVID-19 in India: An open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial) – medRxiv

 

Commentary on Twitter

 

The coronavirus is mutating — does it matter?

9 Sep, 2020 | 09:35h | UTC

The coronavirus is mutating — does it matter? – Nature

 

The immunology of multisystem inflammatory syndrome in children with COVID-19

9 Sep, 2020 | 09:33h | UTC

The Immunology of Multisystem Inflammatory Syndrome in Children with COVID-19 – Cell

 

Perspective: “When will WE have a vaccine?” — understanding questions and answers about Covid-19 vaccination

9 Sep, 2020 | 09:37h | UTC

“When Will We Have a Vaccine?” — Understanding Questions and Answers about Covid-19 Vaccination – New England Journal of Medicine

 

Commentary on Twitter

 

WHO: Emergency use approval is a “temporary solution,” countries should wait for large clinical trials to finish to roll out a COVID-19 vaccine en masse

8 Sep, 2020 | 01:21h | UTC

Emergency Use Approval Is A “Temporary Solution,” Countries Should Wait For Large Clinical Trials To Finish To Roll Out A COVID-19 Vaccine En Masse – Health Policy Watch

 

An ethical framework for global vaccine allocation

8 Sep, 2020 | 01:24h | UTC

An ethical framework for global vaccine allocation – Science

Commentary: Who should get the COVID-19 vaccine first? – University of Pennsylvania School of Medicine

 

Commentaries on Twitter

 

Evolution of the COVID-19 vaccine development landscape

8 Sep, 2020 | 01:18h | UTC

Evolution of the COVID-19 vaccine development landscape – Nature Reviews Drug Discovery

 

COVID-19 is, in the end, an endothelial disease

8 Sep, 2020 | 01:11h | UTC

COVID-19 is, in the end, an endothelial disease – European Heart Journal

 

Commentary on Twitter

 

Post-COVID syndrome severely damages children’s hearts; ‘immense inflammation’ causing cardiac blood vessel dilation

6 Sep, 2020 | 22:03h | UTC

Post-COVID syndrome severely damages children’s hearts; ‘immense inflammation’ causing cardiac blood vessel dilation – University of Texas Health Science Center at San Antonio

Original Study: Multisystem inflammatory syndrome in children: A systematic review – EClinicalMedicine

 

Commentary on Twitter

 

Does the COVID-19 cytokine storm exist?

6 Sep, 2020 | 21:55h | UTC

Does the COVID-19 cytokine storm exist? – Radboud University Medical Center

Original Study: Cytokine Levels in Critically Ill Patients With COVID-19 and Other Conditions – JAMA

 

Commentary on Twitter

 

Phase 1–2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine

6 Sep, 2020 | 21:44h | UTC

Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine – New England Journal of Medicine

 

Immunological considerations for COVID-19 vaccine strategies

6 Sep, 2020 | 21:47h | UTC

Immunological considerations for COVID-19 vaccine strategies – Nature Reviews Immunology

 

Commentary on Twitter

 

Russian coronavirus vaccine results have been published

6 Sep, 2020 | 21:48h | UTC

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia – The Lancet

Commentaries: COVID-19 vaccines: early success and remaining challenges – The Lancet AND The Russian vaccine for COVID-19 – The Lancet Respiratory Medicine AND Early-phase Russian trials reveal safety and immunogenicity of two formulations of a two-part vaccine – News Medical / The Lancet AND Russian coronavirus vaccine results have been published – here’s what they reveal – The Conversation

 

Commentary on Twitter

 

Attitudes toward a potential SARS-CoV-2 vaccine: A survey of U.S. adults

6 Sep, 2020 | 21:45h | UTC

Attitudes Toward a Potential SARS-CoV-2 Vaccine: A Survey of U.S. Adults – Annals of Internal Medicine

 

Editorial: Are we underestimating seroprevalence of SARS-CoV-2?

4 Sep, 2020 | 02:17h | UTC

Are we underestimating seroprevalence of SARS-CoV-2? – The BMJ

Commentary: Are antibody tests underestimating the spread of COVID-19? – St. George’s University of London

 

Case report: Autoantibody-negative insulin-dependent diabetes mellitus after SARS-CoV-2 infection

4 Sep, 2020 | 02:10h | UTC

Autoantibody-negative insulin-dependent diabetes mellitus after SARS-CoV-2 infection: a case report – Nature Metabolism

Commentary: Can COVID-19 cause diabetes? – MedicalXpress

 

Commentary on Twitter

 

COVID-19 and mRNA vaccines—first large test for a new approach

4 Sep, 2020 | 02:08h | UTC

COVID-19 and mRNA Vaccines—First Large Test for a New Approach – JAMA

 

Challenges in evaluating SARS-CoV-2 vaccines during the COVID-19 pandemic

4 Sep, 2020 | 02:06h | UTC

Challenges in evaluating SARS-CoV-2 vaccines during the COVID-19 pandemic – Canadian Medical Association Journal

 

Coalition Covid-19 Brazil – Randomized trial: Dexamethasone improves outcomes in patients with Acute Respiratory Distress Syndrome and COVID-19

3 Sep, 2020 | 11:24h | UTC

Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial – JAMA

Editorial: Corticosteroids in COVID-19 ARDS: Evidence and Hope During the Pandemic

Related studies: Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial – JAMA AND Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19: A Randomized Clinical Trial – JAMA

Commentary: Inexpensive Steroids Can Save Lives Of Seriously Ill COVID-19 Patients – NPR

 

Commentary on Twitter

 

Meta-analysis: Corticosteroids for critically ill patients with COVID-19

3 Sep, 2020 | 11:23h | UTC

Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis – JAMA

Editorial: Corticosteroids in COVID-19 ARDS: Evidence and Hope During the Pandemic

Commentaries: Analysis of seven trials finds that corticosteroids reduce risk of death by 20 per cent in critically ill COVID-19 patients – University of Bristol  AND Multiple studies confirm steroids can fight severe COVID-19 – MedicalXpress

 

Commentary on Twitter

 

[Preprint] Randomized trial: Tocilizumab does not improve clinical status or mortality in hospitalized patients with COVID-19 pneumonia

3 Sep, 2020 | 11:19h | UTC

Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia – medRxiv

 

Covid-19: Study found those younger than 40 had an infection fatality ratio (IFR) of 0.01%; those 60 or older had an IFR of 1.71%

3 Sep, 2020 | 11:18h | UTC

Infection Fatality Ratios for COVID-19 Among Noninstitutionalized Persons 12 and Older: Results of a Random-Sample Prevalence Study – Annals of Internal Medicine

 

Commentary on Twitter

 

Humoral immune response to SARS-CoV-2 in Iceland

2 Sep, 2020 | 09:57h | UTC

Humoral Immune Response to SARS-CoV-2 in Iceland – New England Journal of Medicine

Editorial: The Power of Antibody-Based Surveillance

 

Commentary on Twitter

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.